Quest Diagnostics Incorporated (NYSE:DGX) Chairman Stephen H. Rusckowski sold 2,525 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $108.03, for a total transaction of $272,775.75. Following the sale, the chairman now owns 168,413 shares in the company, valued at $18,193,656.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Quest Diagnostics Incorporated (NYSE DGX) traded up 0.03% during trading on Thursday, reaching $107.29. The company had a trading volume of 552,436 shares. The firm has a 50-day moving average price of $107.38 and a 200-day moving average price of $104.85. Quest Diagnostics Incorporated has a 52-week low of $79.12 and a 52-week high of $112.97. The company has a market capitalization of $14.63 billion, a P/E ratio of 21.62 and a beta of 0.69.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The business had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same period last year, the business posted $1.34 EPS. The company’s revenue was up 1.9% on a year-over-year basis. On average, analysts predict that Quest Diagnostics Incorporated will post $5.69 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Monday, October 2nd. This represents a $1.80 annualized dividend and a yield of 1.68%. Quest Diagnostics’s dividend payout ratio is presently 36.29%.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/07/insider-selling-quest-diagnostics-incorporated-dgx-chairman-sells-2525-shares-of-stock.html.

A number of hedge funds have recently bought and sold shares of the business. Schnieders Capital Management LLC increased its holdings in Quest Diagnostics by 0.3% during the 2nd quarter. Schnieders Capital Management LLC now owns 2,366 shares of the medical research company’s stock worth $263,000 after purchasing an additional 6 shares during the last quarter. Parallel Advisors LLC increased its holdings in Quest Diagnostics by 0.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock worth $140,000 after purchasing an additional 12 shares during the last quarter. First American Trust FSB increased its holdings in Quest Diagnostics by 0.3% during the 2nd quarter. First American Trust FSB now owns 4,395 shares of the medical research company’s stock worth $489,000 after purchasing an additional 14 shares during the last quarter. YorkBridge Wealth Partners LLC increased its holdings in Quest Diagnostics by 1.5% during the 1st quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock worth $127,000 after purchasing an additional 18 shares during the last quarter. Finally, Hills Bank & Trust Co. increased its holdings in Quest Diagnostics by 1.4% during the 2nd quarter. Hills Bank & Trust Co. now owns 2,560 shares of the medical research company’s stock worth $285,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 87.07% of the company’s stock.

A number of analysts have issued reports on DGX shares. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Zacks Investment Research lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, May 22nd. BidaskClub lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Credit Suisse Group reiterated a “neutral” rating and set a $110.00 price target (up from $83.00) on shares of Quest Diagnostics in a research note on Thursday, July 13th. They noted that the move was a valuation call. Finally, Bank of America Corporation reiterated a “neutral” rating and set a $110.00 price target (up from $105.00) on shares of Quest Diagnostics in a research note on Sunday, May 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $109.62.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.